Advertisement
Table 4 On-treatment and post-treatment failure by trial phase (ITT population)
| n/N (%) | Phase 2/3 group (N = 125) | Phase 1 group (N = 16) |
|---|---|---|
| Failure | 38/125 (30.4) | 10/16 (62.5) |
| On-treatment failure | 20/125 (16.0) | 3/16 (18.8) |
| Met stopping rule at Week 4/12/24/36 | 13/125 (10.4) | 0/16 |
| Other (detectable at EOT) | 5/125 (4.0) | 2/16 (12.5) |
| Viral breakthrough | 2/125 (1.6) | 1/16 (6.3) |
| Completed PegIFNα-2a and/or RBV | 3/125 (2.4) | 0/16 |
| Met stopping rule at Week 4/12/24/36 | 1/125 (0.8) | 0/16 |
| Other (detectable at EOT) | 1/125 (0.8) | 0/16 |
| Viral breakthrough | 1/125 (0.8) | 0/16 |
| Discontinued PegIFNα-2a and RBV | 17/125 (13.6) | 3/16 (18.8) |
| Met stopping rule at Week 4/12/24/36 | 12/125 (9.6) | 0/16 |
| Other (detectable at EOT) | 4/125 (3.2) | 2/16 (12.5) |
| Viral breakthrough | 1/125 (0.8) | 1/16 (6.3) |
| Post-treatment failure | 18/125 (14.4) | 7/16 (43.8) |
| Viral relapse | 15/125 (12.0) | 5/16 (31.3) |
| Discontinued PegIFNα-2a and RBV | 3/125 (2.4) | 3/16 (18.8) |
| Completed PegIFNα-2a and/or RBV | 12/125 (9.6) | 2/16 (12.5) |
| Missing at time point of SVR12 | 3/125 (2.4) | 2/16 (12.5) |
